Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion
Titel:
Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion
Auteur:
Ezekowitz, Michael D. Cappato, Riccardo Klein, Allan L. Camm, A. John Ma, Chang-Sheng Le Heuzey, Jean-Yves Talajic, Mario Scanavacca, MaurĂcio I. Vardas, Panos E. Kirchhof, Paulus Hohnloser, Stefan H. Hemmrich, Melanie Lanius, Vivian Meng, Isabelle Ling Wildgoose, Peter van Eickels, Martin